Movement Alert｜3SBio Falls 5.64% in Regular Trading, Institutional Selling Compounds Biotech Sector Pullback

Market Focus07-17 10:09

On July 17, 3SBio fell 5.64% in regular trading, trading at 16.35 HKD/share, with turnover of HKD 357 million.

On the news front, Orient Securities sold 6.131 million shares of 3SBio on July 10 at approximately HKD 17.87 per share, totaling around HKD 110 million, reducing its stake to 6.97%. Earlier, Huatai-PineBridge Fund also reduced its holding by 6.131 million shares at a similar price on July 14. Consecutive institutional disposals have weighed heavily on market sentiment.

The broader Biotechnology sector also saw broad-based weakness, with AKESO down 9.09%, Remegen down 7.35%, SKB Bio down 4.92%, Innovent Bio down 3.66%, and BeiGene down 2.62%, amplifying selling pressure on 3SBio.

3SBio is an investment holding company principally engaged in the development, production, marketing, and sale of biopharmaceutical products, including Tpiao, Epiao, and Yisaipu, with operations also covering CDMO services.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1129482072?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 10:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129482072","market":"hk","top_or_hot":-1,"title":"Movement Alert｜3SBio Falls 5.64% in Regular Trading, Institutional Selling Compounds Biotech Sector Pullback","media":"Market Focus","content":"<p><p>On July 17, 3SBio fell 5.64% in regular trading, trading at 16.35 HKD/share, with turnover of HKD 357 million.</p><p>On the news front, Orient Securities sold 6.131 million shares of 3SBio on July 10 at approximately HKD 17.87 per share, totaling around HKD 110 million, reducing its stake to 6.97%. Earlier, Huatai-PineBridge Fund also reduced its holding by 6.131 million shares at a similar price on July 14. Consecutive institutional disposals have weighed heavily on market sentiment.</p><p>The broader Biotechnology sector also saw broad-based weakness, with AKESO down 9.09%, Remegen down 7.35%, SKB Bio down 4.92%, Innovent Bio down 3.66%, and BeiGene down 2.62%, amplifying selling pressure on 3SBio.</p><p>3SBio is an investment holding company principally engaged in the development, production, marketing, and sale of biopharmaceutical products, including Tpiao, Epiao, and Yisaipu, with operations also covering CDMO services.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜3SBio Falls 5.64% in Regular Trading, Institutional Selling Compounds Biotech Sector Pullback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜3SBio Falls 5.64% in Regular Trading, Institutional Selling Compounds Biotech Sector Pullback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-17 10:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 17, 3SBio fell 5.64% in regular trading, trading at 16.35 HKD/share, with turnover of HKD 357 million.</p><p>On the news front, Orient Securities sold 6.131 million shares of 3SBio on July 10 at approximately HKD 17.87 per share, totaling around HKD 110 million, reducing its stake to 6.97%. Earlier, Huatai-PineBridge Fund also reduced its holding by 6.131 million shares at a similar price on July 14. Consecutive institutional disposals have weighed heavily on market sentiment.</p><p>The broader Biotechnology sector also saw broad-based weakness, with AKESO down 9.09%, Remegen down 7.35%, SKB Bio down 4.92%, Innovent Bio down 3.66%, and BeiGene down 2.62%, amplifying selling pressure on 3SBio.</p><p>3SBio is an investment holding company principally engaged in the development, production, marketing, and sale of biopharmaceutical products, including Tpiao, Epiao, and Yisaipu, with operations also covering CDMO services.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1129482072","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129482072","pubTimestamp":1784254168,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 17, 3SBio fell 5.64% in regular trading, trading at 16.35 HKD/share, with turnover of HKD 357 million.On the news front, Orient Securities sold 6.131 million shares of 3SBio on July 10 at...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"走势提醒|3SBio常规交易下跌5.64%，机构抛售加剧生物技术板块回调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"On July 17, 3SBio fell 5.64% in regular trading, trading at 16.35 HKD/share, with turnover of HKD 357 million.On the news front, Orient Securities sold 6.131 million shares of 3SBio on July 10 at approximately HKD 17.87 per share, totaling around HKD 110 million, reducing its stake to 6.97%. Earlier, Huatai-PineBridge Fund also reduced its holding by 6.131 million shares at a similar price on July 14. Consecutive institutional disposals have weighed heavily on market sentiment.The broader Biotechnology sector also saw broad-based weakness, with AKESO down 9.09%, Remegen down 7.35%, SKB Bio down 4.92%, Innovent Bio down 3.66%, and BeiGene down 2.62%, amplifying selling pressure on 3SBio.3SBio is an investment holding company principally engaged in the development, production, marketing, and sale of biopharmaceutical products, including Tpiao, Epiao, and Yisaipu, with operations also covering CDMO services.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1129482072","isCrawlerRequest":true}